Adults
The recommended dose of INVEGA (paliperidone) Extended-Release Tablets for the treatment of schizophrenia in adults is 6 mg administered once daily. Initial dose titration is not required. Although it has not been systematically established that doses above 6 mg have additional benefit, there was a general trend for greater effects with higher doses. This must be weighed against the dose-related increase in adverse reactions. Thus, some patients may benefit from higher doses, up to 12 mg/day, and for some patients, a lower dose of 3 mg/day may be sufficient. Dose increases above 6 mg/day should be made only after clinical reassessment and generally should occur at intervals of more than 5 days. When dose increases are indicated, increments of 3 mg/day are recommended. The maximum recommended dose is 12 mg/day.
In a longer-term study, INVEGA has been shown to be effective in delaying time to relapse in patients with schizophrenia who were stabilized on INVEGA for 6 weeks
[see
Clinical Studies (14)]
. INVEGA should be prescribed at the lowest effective dose for maintaining clinical stability and the physician should periodically reevaluate the long-term usefulness of the drug in individual patients.
Adolescents (12–17 years of age)
The recommended starting dose of INVEGA (paliperidone) Extended-Release Tablets for the treatment of schizophrenia in adolescents 12–17 years of age is 3 mg administered once daily. Initial dose titration is not required. Dose increases, if considered necessary, should be made only after clinical reassessment and should occur at increments of 3 mg/day at intervals of more than 5 days. Prescribers should be mindful that, in the adolescent schizophrenia study, there was no clear enhancement to efficacy at the higher doses, i.e., 6 mg for subjects weighing less than 51 kg and 12 mg for subjects weighing 51 kg or greater, while adverse events were dose-related.
Renal Impairment
Dosing must be individualized according to the patient's renal function status. For patients with mild renal impairment (creatinine clearance ≥ 50 mL/min to < 80 mL/min), the recommended initial dose of INVEGA is 3 mg once daily. The dose may then be increased to a maximum of 6 mg once daily based on clinical response and tolerability. For patients with moderate to severe renal impairment (creatinine clearance ≥ 10 mL/min to < 50 mL/min), the recommended initial dose of INVEGA is 3 mg every other day, which may be increased to a maximum of 3 mg once daily after clinical reassessment. As INVEGA has not been studied in patients with creatinine clearance below 10 mL/min, use is not recommended in such patients.
[See
Clinical Pharmacology (12.3)]
Hepatic Impairment
For patients with mild to moderate hepatic impairment, (Child-Pugh Classification A and B), no dose adjustment is recommended
[see
Clinical Pharmacology (12.3)]
. INVEGA has not been studied in patients with severe hepatic impairment.
Elderly
Because elderly patients may have diminished renal function, dose adjustments may be required according to their renal function status. In general, recommended dosing for elderly patients with normal renal function is the same as for younger adult patients with normal renal function. For patients with moderate to severe renal impairment (creatinine clearance 10 mL/min to < 50 mL/min), the maximum recommended dose of INVEGA is 3 mg once daily
[see
Renal Impairment above]
.
Hyperglycemia and Diabetes Mellitus
Hyperglycemia and diabetes mellitus, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, have been reported in patients treated with all atypical antipsychotics. These cases were, for the most part, seen in postmarketing clinical use and epidemiologic studies, not in clinical trials, and there have been few reports of hyperglycemia or diabetes in trial subjects treated with INVEGA. Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and hyperglycemia-related adverse events is not completely understood. However, epidemiological studies suggest an increased risk of treatment-emergent hyperglycemia-related adverse events in patients treated with the atypical antipsychotics. Because INVEGA was not marketed at the time these studies were performed, it is not known if INVEGA is associated with this increased risk.
Patients with an established diagnosis of diabetes mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glucose control. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.
Pooled data from the three placebo-controlled, 6-week, fixed-dose studies in adult subjects with schizophrenia are presented in Table 1a.
Table 1a. Change in Fasting Glucose from Three Placebo-Controlled, 6-Week, Fixed-Dose Studies in Adult Subjects with Schizophrenia | | | INVEGA | |
|---|
| Placebo | 3 mg/day | 6 mg/day | 9 mg/day | 12 mg/day |
|---|
| Mean change from baseline (mg/dL) |
| n=322 | n=122 | n=212 | n=234 | n=218 |
Serum Glucose
Change from baseline
| 0.8 | -0.7 | 0.4 | 2.3 | 4.3 |
| Proportion of Patients with Shifts |
Serum Glucose
Normal to High
| 5.1% | 3.2% | 4.5% | 4.8% | 3.8% |
| (<100 mg/dL to ≥126 mg/dL) | (12/236) | (3/93) | (7/156) | (9/187) | (6/157) |
In the uncontrolled, longer-term open-label extension studies, INVEGA was associated with a mean change in glucose of +3.3 mg/dL at Week 24 (n=570) and +4.6 mg/dL at Week 52 (n=314).
Data from the placebo-controlled 6-week study in adolescent subjects (12–17 years of age) with schizophrenia are presented in Table 1b.
Table 1b. Change in Fasting Glucose from a Placebo-Controlled 6-Week Study in Adolescent Subjects (12–17 years of age) with Schizophrenia | | INVEGA |
|---|
| Placebo | 1.5 mg/day | 3 mg/day | 6 mg/day | 12 mg/day |
|---|
| Mean change from baseline (mg/dL) |
| n=41 | n=44 | n=11 | n=28 | n=32 |
Serum Glucose
Change from baseline
| 0.8 | -1.4 | -1.8 | -0.1 | 5.2 |
| Proportion of Patients with Shifts |
Serum Glucose
Normal to High
| 3% | 0% | 0% | 0% | 11% |
| (<100 mg/dL to ≥126 mg/dL) | (1/32) | (0/34) | (0/9) | (0/20) | (3/27) |
Dyslipidemia
Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.
Pooled data from the three placebo-controlled, 6-week, fixed-dose studies in adult subjects with schizophrenia are presented in Table 2a.
Table 2a. Change in Fasting Lipids from Three Placebo-Controlled, 6-Week, Fixed-Dose Studies in Adult Subjects with Schizophrenia | | INVEGA |
|---|
| Placebo | 3 mg/day | 6 mg/day | 9 mg/day | 12 mg/day |
|---|
| Mean change from baseline (mg/dL) |
| Cholesterol | n=331 | n=120 | n=216 | n=236 | n=231 |
| Change from baseline | -6.3 | -4.4 | -2.4 | -5.3 | -4.0 |
| LDL | n=322 | n=116 | n=210 | n=231 | n=225 |
| Change from baseline | -3.2 | 0.5 | -0.8 | -3.9 | -2.0 |
| HDL | n=331 | n=119 | n=216 | n=234 | n=230 |
| Change from baseline | 0.3 | -0.4 | 0.5 | 0.8 | 1.2 |
| Triglycerides | n=331 | n=120 | n=216 | n=236 | n=231 |
| Change from baseline | -22.3 | -18.3 | -12.6 | -10.6 | -15.4 |
| Proportion of Patients with Shifts |
| Cholesterol | | | | | |
| Normal to High | 2.6% | 2.8% | 5.6% | 4.1% | 3.1% |
| (<200 mg/dL to ≥240 mg/dL) | (5/194) | (2/71) | (7/125) | (6/147) | (4/130) |
| LDL | | | | | |
| Normal to High | 1.9% | 0.0% | 5.0% | 3.7% | 0.0% |
| (<100 mg/dL to ≥160 mg/dL) | (2/105) | (0/44) | (3/60) | (3/81) | (0/69) |
| HDL | | | | | |
| Normal to Low | 22.0% | 16.3% | 29.1% | 23.4% | 20.0% |
| (≥40 mg/dL to <40 mg/dL) | (44/200) | (13/80) | (39/134) | (32/137) | (27/135) |
| Triglycerides | | | | | |
| Normal to High | 5.3% | 11.0% | 8.8% | 8.7% | 4.3% |
| (<150 mg/dL to ≥200 mg/dL) | (11/208) | (9/82) | (12/136) | (13/150) | (6/139) |
In the uncontrolled, longer-term open-label extension studies, INVEGA was associated with a mean change in (a) total cholesterol of -1.5 mg/dL at Week 24 (n=573) and -1.5 mg/dL at Week 52 (n=317), (b) triglycerides of -6.4 mg/dL at Week 24 (n=573) and -10.5 mg/dL at Week 52 (n=317); (c) LDL of -1.9 mg/dL at Week 24 (n=557) and -2.7 mg/dL at Week 52 (n=297); and (d) HDL of +2.2 mg/dL at Week 24 (n=568) and +3.6 mg/dL at Week 52 (n=302).
Data from the placebo-controlled 6-week study in adolescent subjects (12–17 years of age) with schizophrenia are presented in Table 2b.
Table 2b. Change in Fasting Lipids from a Placebo-Controlled 6-Week Study in Adolescent Subjects (12–17 years of age) with Schizophrenia | | INVEGA |
|---|
| Placebo | 1.5 mg/day | 3 mg/day | 6 mg/day | 12 mg/day |
|---|
| Mean change from baseline (mg/dL) |
| Cholesterol | n=39 | n=45 | n=11 | n=28 | n=32 |
| Change from baseline | -7.8 | -3.3 | 12.7 | 3.0 | -1.5 |
| LDL | n=37 | n=40 | n=9 | n=27 | n=31 |
| Change from baseline | -4.1 | -3.1 | 7.2 | 2.4 | 0.6 |
| HDL | n=37 | n=41 | n=9 | n=27 | n=31 |
| Change from baseline | -1.9 | 0.0 | 1.3 | 1.4 | 0.0 |
| Triglycerides | n=39 | n=44 | n=11 | n=28 | n=32 |
| Change from baseline | -8.9 | 3.2 | 17.6 | -5.4 | 3.9 |
| Proportion of Patients with Shifts |
| Cholesterol | | | | | |
| Normal to High | 7% | 4% | 0% | 6% | 11% |
| (<170 mg/dL to ≥200 mg/dL) | (2/27) | (1/26) | (0/6) | (1/18) | (2/19) |
| LDL | | | | | |
| Normal to High | 3% | 4% | 14% | 0% | 9% |
| (<110 mg/dL to ≥130 mg/dL) | (1/32) | (1/25) | (1/7) | (0/22) | (2/22) |
| HDL | | | | | |
| Normal to Low | 14% | 7% | 29% | 13% | 23% |
| (≥40 mg/dL to <40 mg/dL) | (4/28) | (2/30) | (2/7) | (3/23) | (5/22) |
| Triglycerides | | | | | |
| Normal to High | 3% | 5% | 13% | 8% | 7% |
| (<150 mg/dL to ≥200 mg/dL) | (1/34) | (2/38) | (1/8) | (2/26) | (2/28) |
Weight Gain
Weight gain has been observed with atypical antipsychotic use. Clinical monitoring of weight is recommended.
Schizophrenia Trials
Data on mean changes in body weight and the proportion of subjects meeting a weight gain criterion of ≥ 7% of body weight from the three placebo-controlled, 6-week, fixed-dose studies in adult subjects are presented in Table 3a.
Table 3a. Mean Change in Body Weight (kg) and the Proportion of Subjects with ≥ 7% Gain in Body Weight from Three Placebo-Controlled, 6-Week, Fixed-Dose Studies in Adult Subjects with Schizophrenia | | INVEGA |
|---|
| Placebo | 3 mg/day | 6 mg/day | 9 mg/day | 12 mg/day |
|---|
| n=323 | n=112 | n=215 | n=235 | n=218 |
|---|
Weight (kg)
Change from baseline
| -0.4 | 0.6 | 0.6 | 1.0 | 1.1 |
Weight Gain
≥ 7% increase from baseline
| 5% | 7% | 6% | 9% | 9% |
In the uncontrolled, longer-term open-label extension studies, INVEGA was associated with a mean change in weight of +1.4 kg at Week 24 (n=63) and +2.6 kg at Week 52 (n=302).
Weight gain in adolescent subjects with schizophrenia was assessed in a 6-week, double-blind, placebo-controlled study and an open-label extension with a median duration of exposure to INVEGA of 182 days. Data on mean changes in body weight and the proportion of subjects meeting a weight gain criterion of ≥ 7% of body weight
[see
Clinical Studies (14.1)]
from the placebo-controlled 6-week study in adolescent subjects (12–17 years of age) are presented in Table 3b.
Table 3b. Mean Change in Body Weight (kg) and the Proportion of Subjects with ≥ 7% Gain in Body Weight from a Placebo-Controlled 6-Week Study in Adolescent Subjects (12–17 years of age) with Schizophrenia | | INVEGA |
|---|
| Placebo | 1.5 mg/day | 3 mg/day | 6 mg/day | 12 mg/day |
|---|
| n=51 | n=54 | n=16 | n=45 | n=34 |
|---|
Weight (kg)
Change from baseline
| 0.0 | 0.3 | 0.8 | 1.2 | 1.5 |
Weight Gain
≥ 7% increase from baseline
| 2% | 6% | 19% | 7% | 18% |
In the open-label long-term study the proportion of total subjects treated with INVEGA with an increase in body weight of ≥ 7% from baseline was 33%. When treating adolescent patients with INVEGA, weight gain should be assessed against that expected with normal growth. When taking into consideration the median duration of exposure to INVEGA in the open-label study (182 days) along with expected normal growth in this population based on age and gender, an assessment of standardized scores relative to normative data provides a more clinically relevant measure of changes in weight. The mean change from open-label baseline to endpoint in standardized score for weight was 0.1 (4% above the median for normative data). Based on comparison to the normative data, these changes are not considered to be clinically significant.
Schizoaffective Disorder Trials
In the pooled data from the two placebo-controlled, 6-week studies in adult subjects with schizoaffective disorder, a higher percentage of INVEGA-treated subjects (5%) had an increase in body weight of ≥ 7% compared with placebo-treated subjects (1%). In the study that examined high- and low-dose groups, the increase in body weight of ≥ 7% was 3% in the low-dose group, 7% in the high-dose group, and 1% in the placebo group.
Commonly-Observed Adverse Reactions in Double-Blind, Placebo-Controlled Clinical Trials – Schizophrenia in Adults and Adolescents
Adult Patients with Schizophrenia
Table 4 enumerates the pooled incidences of adverse reactions reported in the three placebo-controlled, 6-week, fixed-dose studies in adults, listing those that occurred in 2% or more of subjects treated with INVEGA in any of the dose groups, and for which the incidence in INVEGA-treated subjects in any of the dose groups was greater than the incidence in subjects treated with placebo.
Table 4. Adverse Reactions Reported by ≥ 2% of INVEGA-Treated Adult Subjects with Schizophrenia in Three Short-Term, Fixed-Dose, Placebo-Controlled Clinical Trials
Table includes adverse reactions that were reported in 2% or more of subjects in any of the INVEGA dose groups and which occurred at greater incidence than in the placebo group. Data are pooled from three studies; one study included once-daily INVEGA doses of 3 mg and 9 mg, the second study included 6 mg, 9 mg, and 12 mg, and the third study included 6 mg and 12 mg [see Clinical Studies (14)] . Extrapyramidal symptoms includes the terms dyskinesia, dystonia, extrapyramidal disorder, hypertonia, muscle rigidity, oculogyration, parkinsonism, and tremor. Somnolence includes the terms sedation and somnolence. Tachycardia includes the terms tachycardia, sinus tachycardia, and heart rate increased. Adverse reactions for which the INVEGA incidence was equal to or less than placebo are not listed in the table, but included the following: vomiting.
| Percentage of Patients |
|---|
| | INVEGA |
|---|
| Placebo | 3 mg once daily | 6 mg once daily | 9 mg once daily | 12 mg once daily |
|---|
| Body System or Organ Class | (N=355) | (N=127) | (N=235) | (N=246) | (N=242) |
|---|
| Dictionary-Derived Term | | | | | |
|---|
| Total percentage of subjects with adverse reactions | 37 | 48 | 47 | 53 | 59 |
Cardiac disorders | | | | | |
| Atrioventricular block first degree | 1 | 2 | 0 | 2 | 1 |
| Bundle branch block | 2 | 3 | 1 | 3 | <1 |
| Sinus arrhythmia | 0 | 2 | 1 | 1 | <1 |
| Tachycardia | 7 | 14 | 12 | 12 | 14 |
Gastrointestinal disorders | | | | | |
| Abdominal pain upper | 1 | 1 | 3 | 2 | 2 |
| Dry mouth | 1 | 2 | 3 | 1 | 3 |
| Salivary hypersecretion | <1 | 0 | <1 | 1 | 4 |
General disorders | | | | | |
| Asthenia | 1 | 2 | <1 | 2 | 2 |
| Fatigue | 1 | 2 | 1 | 2 | 2 |
Nervous system disorders | | | | | |
| Akathisia | 4 | 4 | 3 | 8 | 10 |
| Dizziness | 4 | 6 | 5 | 4 | 5 |
| Extrapyramidal symptoms | 8 | 10 | 7 | 20 | 18 |
| Headache | 12 | 11 | 12 | 14 | 14 |
| Somnolence | 7 | 6 | 9 | 10 | 11 |
Vascular disorders | | | | | |
| Orthostatic hypotension | 1 | 2 | 1 | 2 | 4 |
Adolescent Patients with Schizophrenia
Table 5 lists the adverse reactions reported in a fixed-dose, placebo-controlled study in adolescent subjects 12–17 years of age with schizophrenia, listing those that occurred in 2% or more of subjects treated with INVEGA in any of the dose groups, and for which the incidence in INVEGA-treated subjects in any of the dose groups was greater than the incidence in subjects treated with placebo.
Table 5. Adverse Reactions Reported by ≥ 2% of INVEGA-Treated Adolescent Subjects with Schizophrenia in a Fixed-Dose, Placebo-Controlled Clinical Trial
Table includes adverse reactions that were reported in 2% or more of subjects in any of the INVEGA dose groups and which occurred at greater incidence than in the placebo group. Extrapyramidal symptoms includes the terms oculogyric crisis, muscle rigidity, musculoskeletal stiffness, nuchal rigidity, torticollis, trismus, bradykinesia, cogwheel rigidity, dyskinesia, dystonia, extrapyramidal disorder, hypertonia, hypokinesia, muscle contractions involuntary, parkinsonian gait, parkinsonism, tremor, and restlessness. Somnolence includes the terms somnolence, sedation, and hypersomnia. Insomnia includes the terms insomnia and initial insomnia. Tachycardia includes the terms tachycardia, sinus tachycardia, and heart rate increased. Hypertension includes the terms hypertension and blood pressure increased. Gynecomastia includes the terms gynecomastia and breast swelling.
| Percentage of Patients |
|---|
| | INVEGA |
|---|
| Placebo | 1.5 mg once daily | 3 mg once daily | 6 mg once daily | 12 mg once daily |
|---|
| Body System or Organ Class | (N=51) | (N=54) | (N=16) | (N=45) | (N=35) |
|---|
| Dictionary-Derived Term | | | | | |
|---|
| Total percentage of subjects with adverse reactions | 43 | 37 | 50 | 58 | 74 |
Cardiac disorders | | | | | |
| Tachycardia | 0 | 0 | 6 | 9 | 6 |
Eye disorders | | | | | |
| Vision blurred | 0 | 0 | 0 | 0 | 3 |
Gastrointestinal disorders | | | | | |
| Dry mouth | 2 | 0 | 0 | 0 | 3 |
| Salivary hypersecretion | 0 | 2 | 6 | 2 | 0 |
| Swollen tongue | 0 | 0 | 0 | 0 | 3 |
| Vomiting | 10 | 0 | 6 | 11 | 3 |
General disorders | | | | | |
| Asthenia | 0 | 0 | 0 | 2 | 3 |
| Fatigue | 0 | 4 | 0 | 2 | 3 |
Infections and infestations | | | | |
| Nasopharyngitis | 2 | 4 | 0 | 4 | 0 |
Investigations | | | | | |
| Weight increased | 0 | 7 | 6 | 2 | 3 |
Nervous system disorders | | | | | |
| Akathisia | 0 | 4 | 6 | 11 | 17 |
| Dizziness | 0 | 2 | 6 | 2 | 3 |
| Extrapyramidal symptoms | 0 | 4 | 19 | 18 | 23 |
| Headache | 4 | 9 | 6 | 4 | 14 |
| Lethargy | 0 | 0 | 0 | 0 | 3 |
| Somnolence | 4 | 9 | 13 | 20 | 26 |
| Tongue paralysis | 0 | 0 | 0 | 0 | 3 |
Psychiatric disorders | | | | | |
| Anxiety | 4 | 0 | 0 | 2 | 9 |
Reproductive system and breast disorders | | | |
| Amenorrhea | 0 | 0 | 6 | 0 | 0 |
| Galactorrhea | 0 | 0 | 0 | 4 | 0 |
| Gynecomastia | 0 | 0 | 0 | 0 | 3 |
Respiratory, thoracic and mediastinal disorders | | | |
| Epistaxis | 0 | 0 | 0 | 2 | 0 |
Commonly-Observed Adverse Reactions in Double-Blind, Placebo-Controlled Clinical Trials – Schizoaffective Disorder in Adults
Table 6 enumerates the pooled incidences of adverse reactions reported in the two placebo-controlled 6-week studies in adult subjects, listing those that occurred in 2% or more of subjects treated with INVEGA and for which the incidence in INVEGA -treated subjects was greater than the incidence in subjects treated with placebo.
Table 6. Adverse Drug Reactions Reported by ≥ 2% of INVEGA -Treated Adult Subjects with Schizoaffective Disorder in Two Double-Blind, Placebo-Controlled Clinical Trials
Table includes adverse reactions that were reported in 2% or more of subjects in any of the INVEGA dose groups and which occurred at greater incidence than in the placebo group. Data are pooled from two studies. One study included once-daily INVEGA doses of 6 mg (with the option to reduce to 3 mg) and 12 mg (with the option to reduce to 9 mg). The second study included flexible once-daily doses of 3 to 12 mg. Among the 420 subjects treated with INVEGA, 230 (55%) received INVEGA as monotherapy and 190 (45%) received INVEGA as an adjunct to mood stabilizers and/or antidepressants. Extrapyramidal symptoms includes the terms bradykinesia, drooling, dyskinesia, dystonia, hypertonia, muscle rigidity, muscle twitching, oculogyration, parkinsonian gait, parkinsonism, restlessness, and tremor. Somnolence includes the terms sedation and somnolence. Tachycardia includes the terms tachycardia, sinus tachycardia, and heart rate increased.
| Percentage of Patients |
|---|
| | INVEGA | INVEGA | INVEGA |
|---|
| Placebo | 3–6 mg once-daily fixed-dose range | 9–12 mg once-daily fixed-dose range | 3–12 mg once-daily flexible dose |
|---|
| Body System or Organ Class | (N=202) | (N=108) | (N=98) | (N=214) |
|---|
| Dictionary-Derived Term | | | | |
|---|
| Total percentage of subjects with adverse reactions | 32 | 48 | 50 | 43 |
Cardiac disorders | | | | |
| Tachycardia | 2 | 3 | 1 | 2 |
Gastrointestinal disorders | | | | |
| Abdominal discomfort/Abdominal pain upper | 1 | 1 | 0 | 3 |
| Constipation | 2 | 4 | 5 | 4 |
| Dyspepsia | 2 | 5 | 6 | 6 |
| Nausea | 6 | 8 | 8 | 5 |
| Stomach discomfort | 1 | 0 | 1 | 2 |
General disorders | | | | |
| Asthenia | 1 | 3 | 4 | <1 |
Infections and Infestations | | | | |
| Nasopharyngitis | 1 | 2 | 5 | 3 |
| Rhinitis | 0 | 1 | 3 | 1 |
| Upper respiratory tract infection | 1 | 2 | 2 | 2 |
Investigations | | | | |
| Weight increased | 1 | 5 | 4 | 4 |
Metabolism and nutrition disorders | | | | |
| Decreased appetite | <1 | 1 | 0 | 2 |
| Increased appetite | <1 | 3 | 2 | 2 |
Musculoskeletal and connective tissue disorders | | | | |
| Back pain | 1 | 1 | 1 | 3 |
| Myalgia | <1 | 2 | 4 | 1 |
Nervous system disorders | | | | |
| Akathisia | 4 | 4 | 6 | 6 |
| Dysarthria | 0 | 1 | 4 | 2 |
| Extrapyramidal symptoms | 8 | 20 | 17 | 12 |
| Somnolence | 5 | 12 | 12 | 8 |
Psychiatric disorders | | | | |
| Sleep disorder | <1 | 2 | 3 | 0 |
Respiratory, thoracic and mediastinal disorders | | | | |
| Cough | 1 | 1 | 3 | 1 |
| Pharyngolaryngeal pain | <1 | 0 | 2 | 1 |
Monotherapy versus Adjunctive Therapy
The designs of the two placebo-controlled, 6-week, double-blind trials in adult subjects with schizoaffective disorder included the option for subjects to receive antidepressants (except monoamine oxidase inhibitors) and/or mood stabilizers (lithium, valproate, or lamotrigine). In the subject population evaluated for safety, 230 (55%) subjects received INVEGA as monotherapy and 190 (45%) subjects received INVEGA as an adjunct to mood stabilizers and/or antidepressants. When comparing these 2 subpopulations, only nausea occurred at a greater frequency (≥ 3% difference) in subjects receiving INVEGA as monotherapy.
Discontinuations Due to Adverse Reactions
Schizophrenia Trials
The percentages of subjects who discontinued due to adverse reactions in the three schizophrenia placebo-controlled, 6-week, fixed-dose studies in adults were 3% and 1% in INVEGA- and placebo-treated subjects, respectively. The most common reasons for discontinuation were nervous system disorders (2% and 0% in INVEGA- and placebo-treated subjects, respectively).
Among the adverse reactions in the 6-week, fixed-dose, placebo-controlled study in adolescents with schizophrenia, only dystonia led to discontinuation (<1% of INVEGA-treated subjects).
Schizoaffective Disorder Trials
The percentages of subjects who discontinued due to adverse reactions in the two schizoaffective disorder placebo-controlled 6-week studies in adults were 1% and <1% in INVEGA- and placebo-treated subjects, respectively. The most common reasons for discontinuation were gastrointestinal disorders (1% and 0% in INVEGA- and placebo-treated subjects, respectively).
Dose-Related Adverse Reactions
Schizophrenia Trials
Based on the pooled data from the three placebo-controlled, 6-week, fixed-dose studies in adult subjects with schizophrenia, among the adverse reactions that occurred with a greater than 2% incidence in the subjects treated with INVEGA, the incidences of the following adverse reactions increased with dose: somnolence, orthostatic hypotension, akathisia, dystonia, extrapyramidal disorder, hypertonia, parkinsonism, and salivary hypersecretion. For most of these, the increased incidence was seen primarily at the 12 mg dose, and, in some cases, the 9 mg dose.
In the 6-week, fixed-dose, placebo-controlled study in adolescents with schizophrenia, among the adverse reactions that occurred with >2% incidence in the subjects treated with INVEGA, the incidences of the following adverse reactions increased with dose: tachycardia, akathisia, extrapyramidal symptoms, somnolence, and headache.
Schizoaffective Disorder Trials
In a placebo-controlled, 6-week, high- and low-dose study in adult subjects with schizoaffective disorder, akathisia, dystonia, dysarthria, myalgia, nasopharyngitis, rhinitis, cough, and pharyngolaryngeal pain occurred more frequently (i.e., a difference of at least 2%) in subjects who received higher doses of INVEGA compared with subjects who received lower doses.
Demographic Differences
An examination of population subgroups in the three placebo-controlled, 6-week, fixed-dose studies in adult subjects with schizophrenia and in the two placebo-controlled, 6-week studies in adult subjects with schizoaffective disorder did not reveal any evidence of clinically relevant differences in safety on the basis of gender or race alone; there was also no difference on the basis of age
[see
Use in Specific Populations (8.5)]
.
Extrapyramidal Symptoms (EPS)
Pooled data from the three placebo-controlled, 6-week, fixed-dose studies in adult subjects with schizophrenia provided information regarding treatment-emergent EPS. Several methods were used to measure EPS: (1) the Simpson-Angus global score (mean change from baseline) which broadly evaluates Parkinsonism, (2) the Barnes Akathisia Rating Scale global clinical rating score (mean change from baseline) which evaluates akathisia, (3) use of anticholinergic medications to treat emergent EPS (
Table 7), and (4) incidence of spontaneous reports of EPS (
Table 8). For the Simpson-Angus Scale, spontaneous EPS reports and use of anticholinergic medications, there was a dose-related increase observed for the 9 mg and 12 mg doses. There was no difference observed between placebo and INVEGA 3 mg and 6 mg doses for any of these EPS measures.
Table 7. Treatment-Emergent Extrapyramidal Symptoms (EPS) Assessed by Incidence of Ratings Scales and Use of Anticholinergic Medication – Schizophrenia Studies in Adults | Percentage of Patients |
|---|
| INVEGA |
|---|
| Placebo | 3 mg once daily | 6 mg once daily | 9 mg once daily | 12 mg once daily |
|---|
| EPS Group | (N=355) | (N=127) | (N=235) | (N=246) | (N=242) |
|---|
| Parkinsonism
For Parkinsonism, percent of patients with Simpson-Angus global score > 0.3 (Global score defined as total sum of items score divided by the number of items) | 9 | 11 | 3 | 15 | 14 |
| Akathisia
For Akathisia, percent of patients with Barnes Akathisia Rating Scale global score ≥ 2 | 6 | 6 | 4 | 7 | 9 |
| Use of anticholinergic medications
Percent of patients who received anticholinergic medications to treat emergent EPS | 10 | 10 | 9 | 22 | 22 |
Table 8. Treatment-Emergent Extrapyramidal Symptoms (EPS)-Related Adverse Events by MedDRA Preferred Term – Schizophrenia Studies in Adults | Percentage of Patients |
|---|
| INVEGA |
|---|
| Placebo | 3 mg once daily | 6 mg once daily | 9 mg once daily | 12 mg once daily |
|---|
| EPS Group | (N=355) | (N=127) | (N=235) | (N=246) | (N=242) |
|---|
| Dyskinesia group includes: Dyskinesia, extrapyramidal disorder, muscle twitching, tardive dyskinesia |
| Dystonia group includes: Dystonia, muscle spasms, oculogyration, trismus |
| Hyperkinesia group includes: Akathisia, hyperkinesia |
Parkinsonism group includes: Bradykinesia, cogwheel rigidity, drooling,
hypertonia, hypokinesia, muscle rigidity, musculoskeletal stiffness, parkinsonism
|
| Tremor group includes: Tremor |
| Overall percentage of patients with EPS-related AE | 11 | 13 | 10 | 25 | 26 |
| Dyskinesia | 3 | 5 | 3 | 8 | 9 |
| Dystonia | 1 | 1 | 1 | 5 | 5 |
| Hyperkinesia | 4 | 4 | 3 | 8 | 10 |
| Parkinsonism | 2 | 3 | 3 | 7 | 6 |
| Tremor | 3 | 3 | 3 | 4 | 3 |
Compared to data from the studies in adults subjects with schizophrenia, pooled data from the two placebo-controlled 6-week studies in adult subjects with schizoaffective disorder showed similar types and frequencies of EPS as measured by rating scales, anticholinergic medication use, and spontaneous reports of EPS-related adverse events. For subjects with schizoaffective disorder, there was no dose-related increase in EPS observed for parkinsonism with the Simpson-Angus scale or akathisia with the Barnes Akathisia Rating Scale. There was a dose-related increase observed with spontaneous EPS reports of hyperkinesia and dystonia and in the use of anticholinergic medications.
Table 9 shows the EPS data from the pooled schizoaffective disorder trials.
Table 9. Treatment-Emergent Extrapyramidal Symptoms (EPS)-Related Adverse Events by MedDRA Preferred Term – Schizoaffective Disorder Studies in Adults | Percentage of Patients |
|---|
| | INVEGA |
|---|
| Placebo | 3–6 mg once-daily fixed-dose range | 9–12 mg once-daily fixed-dose range | 3–12 mg once-daily flexible dose |
|---|
| EPS Group | (N=202) | (N=108) | (N=98) | (N=214) |
|---|
| Dyskinesia group includes: Dyskinesia, muscle twitching |
| Dystonia group includes: Dystonia, muscle spasms, oculogyration |
| Hyperkinesia group includes: Akathisia, hyperkinesia, restlessness |
| Parkinsonism group includes: Bradykinesia, drooling, hypertonia, muscle rigidity, muscle tightness, musculoskeletal stiffness, parkinsonian gait, parkinsonism |
| Tremor group includes: Tremor |
| Overall percentage of patients with EPS-related AE | 11 | 23 | 22 | 17 |
| Dyskinesia | 1 | 3 | 1 | 1 |
| Dystonia | 1 | 2 | 3 | 2 |
| Hyperkinesia | 5 | 5 | 8 | 7 |
| Parkinsonism | 3 | 14 | 7 | 7 |
| Tremor | 3 | 12 | 11 | 5 |
The incidences of EPS-related adverse events in the adolescent schizophrenia studies showed a similar dose-related pattern to those in the adult studies. There were notably higher incidences of dystonia, hyperkinesia, tremor, and parkinsonism in the adolescent population as compared to the adult studies
(Table 10).
Table 10. Treatment-Emergent Extrapyramidal Symptoms (EPS)-Related Adverse Events by MedDRA Preferred Term – Schizophrenia Studies in Adolescent Subjects | Percentage of Patients |
|---|
| | INVEGA |
|---|
| Placebo | 1.5 mg once daily | 3 mg once daily | 6 mg once daily | 12 mg once daily |
|---|
| EPS Group | (N=51) | (N=54) | (N=16) | (N=45) | (N=35) |
|---|
| Hyperkinesia group includes: Akathisia |
| Dystonia group includes: Dystonia, muscle contracture, oculogyric crisis, tongue paralysis, torticollis |
| Tremor group includes: Tremor |
| Parkinsonism group includes: Cogwheel rigidity, extrapyramidal disorder, muscle rigidity |
| Dyskinesia group includes: Dyskinesia, muscle contractions involuntary |
| Overall percentage of patients with EPS-related AE | 0 | 6 | 25 | 22 | 40 |
| Hyperkinesia | 0 | 4 | 6 | 11 | 17 |
| Dystonia | 0 | 2 | 0 | 11 | 14 |
| Tremor | 0 | 2 | 6 | 7 | 11 |
| Parkinsonism | 0 | 0 | 6 | 2 | 14 |
| Dyskinesia | 0 | 2 | 6 | 2 | 6 |
Dystonia
Class Effect:Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups.
Laboratory Test Abnormalities
In the pooled data from the three placebo-controlled, 6-week, fixed-dose studies in adult subjects with schizophrenia and from the two placebo-controlled, 6-week studies in adult subjects with schizoaffective disorder, between-group comparisons revealed no medically important differences between INVEGA and placebo in the proportions of subjects experiencing potentially clinically significant changes in routine serum chemistry, hematology, or urinalysis parameters. Similarly, there were no differences between INVEGA and placebo in the incidence of discontinuations due to changes in hematology, urinalysis, or serum chemistry, including mean changes from baseline in fasting glucose, insulin, c-peptide, triglyceride, HDL, LDL, and total cholesterol measurements. However, INVEGA was associated with increases in serum prolactin
[see
Warnings and Precautions (5.7)].
Other Adverse Reactions Observed During Premarketing Evaluation of INVEGA
The following additional adverse reactions occurred in < 2% of INVEGA-treated subjects in the above schizophrenia and schizoaffective disorder clinical trial datasets. The following also includes additional adverse reactions reported at any frequency by INVEGA-treated subjects who participated in other clinical studies.
Cardiac disorders: bradycardia, palpitations
Eye disorders: eye movement disorder
Gastrointestinal disorders: flatulence
General disorders: edema
Immune system disorders: anaphylactic reaction
Infections and infestations: urinary tract infection
Investigations:alanine aminotransferase increased, aspartate aminotransferase increased
Musculoskeletal and connective tissue disorders: arthralgia, pain in extremity
Nervous system disorders: opisthotonus
Psychiatric disorders: agitation, insomnia, nightmare
Reproductive system and breast disorders: breast discomfort, menstruation irregular, retrograde ejaculation
Respiratory, thoracic and mediastinal disorders: nasal congestion
Skin and subcutaneous tissue disorders: pruritus, rash
Vascular disorders: hypertension
The safety of INVEGA was also evaluated in a long-term trial designed to assess the maintenance of effect with INVEGA in adults with schizophrenia
[see
Clinical Studies (14)]
. In general, adverse reaction types, frequencies, and severities during the initial 14-week open-label phase of this study were comparable to those observed in the 6-week, placebo-controlled, fixed-dose studies. Adverse reactions reported during the long-term double-blind phase of this study were similar in type and severity to those observed in the initial 14-week open-label phase.
Pregnancy Exposure Registry
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including INVEGA, during pregnancy. Healthcare providers are encouraged to register patients by contacting the National Pregnancy Registry for Atypical Antipsychotics at 1-866-961-2388 or online at http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/.
Risk Summary
Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery
(see
Clinical Considerations)
. Overall, available data from published epidemiologic studies of pregnant women exposed to paliperidone have not established a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes
(see
Data)
. There are risks to the mother associated with untreated schizophrenia and with exposure to antipsychotics, including INVEGA, during pregnancy
(see
Clinical Considerations).
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2–4% and 15–20%, respectively.
In animal reproduction studies, there were no increases in fetal abnormalities when pregnant rats and rabbits were treated with paliperidone during the period of organogenesis with up to 8 times the maximum recommended human dose (MRHD) based on mg/m
2body surface area. Additional reproduction toxicity studies were conducted with orally administered risperidone, which is extensively converted to paliperidone (see
Animal data).
Clinical Considerations
Disease-associated maternal and/or embryo/fetal risk
There is a risk to the mother from untreated schizophrenia, including increased risk of relapse, hospitalization, and suicide. Schizophrenia are associated with increased adverse perinatal outcomes, including preterm birth. It is not known if this is a direct result of the illness or other comorbid factors.
Fetal/Neonatal Adverse Reactions
Extrapyramidal and/or withdrawal symptoms, including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding disorder have been reported in neonates who were exposed to antipsychotic drugs, including INVEGA, during the third trimester of pregnancy. These symptoms have varied in severity. Monitor neonates for extrapyramidal and/or withdrawal symptoms and manage symptoms appropriately. Some neonates recovered within hours or days without specific treatment; others required prolonged hospitalization.
Data
Human Data
Published data from observational studies, birth registries, and case reports on the use of atypical antipsychotics during pregnancy do not report a clear association with antipsychotics and major birth defects. A prospective observational study including 6 women treated with risperidone, the parent compound of paliperidone, demonstrated placental passage of risperidone and paliperidone. A retrospective cohort study from a Medicaid database of 9258 women exposed to antipsychotics during pregnancy did not indicate an overall increased risk for major birth defects. There was a small increase in the risk of major birth defects (RR= 1.26, 95% CI 1.02–1.56) and of cardiac malformations (RR=1.26, 95% CI 0.88–1.81) in a subgroup of 1566 women exposed to the parent compound of paliperidone, risperidone, during the first trimester of pregnancy; however, there is no mechanism of action to explain the difference in malformation rates.
Animal Data
In animal reproduction studies, there were no increases in fetal abnormalities when pregnant rats and rabbits were treated with paliperidone during the period of organogenesis with up to 8 times the MRHD of 12 mg based on mg/m
2 body surface area.
Additional reproduction toxicity studies were conducted with orally administered risperidone, which is extensively converted to paliperidone. Cleft palate was observed in the offspring of pregnant mice treated with risperidone at 3 to 4 times the MRHD of 16 mg based on mg/m
2 body surface area; maternal toxicity occurred at 4 times the MHRD. There was no evidence of teratogenicity in embryo-fetal developmental toxicity studies with risperidone in rats and rabbits at doses up to 6 times the MRHD of 16 mg/day risperidone based on mg/m
2 body surface area. When the offspring of pregnant rats, treated with risperidone at 0.6 times the MRHD based on mg/m
2body surface area, reached adulthood, learning was impaired. Increased neuronal cell death occurred in the fetal brains of the offspring of pregnant rats treated at 0.5 to 1.2 times the MRHD; the postnatal development and growth of the offspring was delayed.
In rat reproduction studies with risperidone, pup deaths occurred at oral doses which are less than the MRHD of risperidone based on mg/m
2 body surface area; it is not known whether these deaths were due to a direct effect on the fetuses or pups or to effects on the dams (see RISPERDAL package insert).
Risk Summary
Limited data from published literature report the presence of paliperidone in human breast milk. There is no information on the effects on the breastfed infant, or the effects on milk production; however, there are reports of sedation, failure to thrive, jitteriness, and extrapyramidal symptoms (tremors and abnormal muscle movements) in breastfed infants exposed to paliperidone's parent compound, risperidone
(see
Clinical Considerations)
. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for INVEGA and any potential adverse effects on the breastfed child from INVEGA or from the mother's underlying condition.
Clinical Considerations
Infants exposed to INVEGA through breastmilk should be monitored for excess sedation, failure to thrive, jitteriness, and extrapyramidal symptoms (tremors and abnormal muscle movements).
Infertility
Females
Based on the pharmacologic action of paliperidone (D
2 receptor antagonism), treatment with INVEGA may result in an increase in serum prolactin levels, which may lead to a reversible reduction in fertility in females of reproductive potential
[see
Warnings and Precautions (5.7)].
Juvenile Animal Studies
In a study in which juvenile rats were treated with oral paliperidone from days 24 to 73 of age, a reversible impairment of performance in a test of learning and memory was seen, in females only, with a no-effect dose of 0.63 mg/kg/day, which produced plasma levels (AUC) of paliperidone similar to those in adolescents at MRHD of 12 mg/day. No other consistent effects on neurobehavioral or reproductive development were seen up to the highest dose tested (2.5 mg/kg/day), which produced plasma levels of paliperidone 2–3 times those in adolescents.
Juvenile dogs were treated for 40 weeks with oral risperidone, which is extensively metabolized to paliperidone in animals and humans, at doses of 0.31, 1.25, or 5 mg/kg/day. Decreased bone length and density were seen with a no-effect dose of 0.31 mg/kg/day, which produced plasma levels (AUC) of risperidone plus paliperidone which were similar to those in children and adolescents receiving the MRHD of risperidone. In addition, a delay in sexual maturation was seen at all doses in both males and females. The above effects showed little or no reversibility in females after a 12-week drug-free recovery period.
The long-term effects of INVEGA on growth and sexual maturation have not been fully evaluated in children and adolescents.
Delivery System Components and Performance
INVEGA uses osmotic pressure to deliver paliperidone at a controlled rate. The delivery system, which resembles a capsule-shaped tablet in appearance, consists of an osmotically active trilayer core surrounded by a subcoat and semipermeable membrane. The trilayer core is composed of two drug layers containing the drug and excipients, and a push layer containing osmotically active components. There are two precision laser-drilled orifices on the drug-layer dome of the tablet. Each tablet strength has a different colored water-dispersible overcoat and print markings. In an aqueous environment, such as the gastrointestinal tract, the water-dispersible color overcoat erodes quickly. Water then enters the tablet through the semipermeable membrane that controls the rate at which water enters the tablet core, which, in turn, determines the rate of drug delivery. The hydrophilic polymers of the core hydrate and swell, creating a gel containing paliperidone that is then pushed out through the tablet orifices. The biologically inert components of the tablet remain intact during gastrointestinal transit and are eliminated in the stool as a tablet shell, along with insoluble core components.
Absorption and Distribution
The absolute oral bioavailability of paliperidone following INVEGA administration is 28%.
Administration of a 12 mg paliperidone extended-release tablet to healthy ambulatory subjects with a standard high-fat/high-caloric meal gave mean C
max and AUC values of paliperidone that were increased by 60% and 54%, respectively, compared with administration under fasting conditions. Clinical trials establishing the safety and efficacy of INVEGA were carried out in subjects without regard to the timing of meals. While INVEGA can be taken without regard to food, the presence of food at the time of INVEGA administration may increase exposure to paliperidone
[see
Dosage and Administration (2.3)]
.
Based on a population analysis, the apparent volume of distribution of paliperidone is 487 L. The plasma protein binding of racemic paliperidone is 74%.
Metabolism and Elimination
Although
in vitro studies suggested a role for CYP2D6 and CYP3A4 in the metabolism of paliperidone,
in vivo results indicate that these isozymes play a limited role in the overall elimination of paliperidone
[see
Drug Interactions (7)]
.
One week following administration of a single oral dose of 1 mg immediate-release
14C-paliperidone to 5 healthy volunteers, 59% (range 51% – 67%) of the dose was excreted unchanged into urine, 32% (26% – 41%) of the dose was recovered as metabolites, and 6% – 12% of the dose was not recovered. Approximately 80% of the administered radioactivity was recovered in urine and 11% in the feces. Four primary metabolic pathways have been identified
in vivo, none of which could be shown to account for more than 10% of the dose: dealkylation, hydroxylation, dehydrogenation, and benzisoxazole scission.
Population pharmacokinetic analyses found no difference in exposure or clearance of paliperidone between extensive metabolizers and poor metabolizers of CYP2D6 substrates.
Special Populations
Renal Impairment
The dose of INVEGA should be reduced in patients with moderate or severe renal impairment
[see
Dosage and Administration (2.5)]
. The disposition of a single dose paliperidone 3 mg extended-release tablet was studied in adult subjects with varying degrees of renal function. Elimination of paliperidone decreased with decreasing estimated creatinine clearance. Total clearance of paliperidone was reduced in subjects with impaired renal function by 32% on average in mild (CrCl = 50 mL/min to < 80 mL/min), 64% in moderate (CrCl = 30 mL/min to < 50 mL/min), and 71% in severe (CrCl = 10 mL/min to < 30 mL/min) renal impairment, corresponding to an average increase in exposure (AUC
inf) of 1.5 fold, 2.6 fold, and 4.8 fold, respectively, compared to healthy subjects. The mean terminal elimination half-life of paliperidone was 24 hours, 40 hours, and 51 hours in subjects with mild, moderate, and severe renal impairment, respectively, compared with 23 hours in subjects with normal renal function (CrCl ≥ 80 mL/min).
Hepatic Impairment
In a study in adult subjects with moderate hepatic impairment (Child-Pugh class B), the plasma concentrations of free paliperidone were similar to those of healthy subjects, although total paliperidone exposure decreased because of a decrease in protein binding. Consequently, no dose adjustment is required in patients with mild or moderate hepatic impairment. INVEGA has not been studied in patients with severe hepatic impairment.
Adolescents (12–17 years of age)
Paliperidone systemic exposure in adolescents weighing ≥ 51 kg (≥ 112 lbs) was similar to that in adults. In adolescents weighing < 51 kg (< 112 lbs), a 23% higher exposure was observed; this is considered not to be clinically significant. Age did not influence the paliperidone exposure.
Elderly
No dosage adjustment is recommended based on age alone. However, dose adjustment may be required because of age-related decreases in creatinine clearance
[see
Renal Impairment above and
Dosage and Administration (2.1,
2.5)]
.
Race
No dosage adjustment is recommended based on race. No differences in pharmacokinetics were observed in a pharmacokinetic study conducted in Japanese and Caucasians.
Gender
No dosage adjustment is recommended based on gender. No differences in pharmacokinetics were observed in a pharmacokinetic study conducted in men and women.
Smoking
No dosage adjustment is recommended based on smoking status. Based on
in vitro studies utilizing human liver enzymes, paliperidone is not a substrate for CYP1A2; smoking should, therefore, not have an effect on the pharmacokinetics of paliperidone.
Carcinogenesis
Carcinogenicity studies with paliperidone administered orally have not been performed.
Carcinogenicity studies with risperidone, which is extensively converted to paliperidone in rats, mice, and humans, were conducted in Swiss albino mice and Wistar rats. Risperidone was administered in the diet at daily doses of 0.63, 2.5, and 10 mg/kg for 18 months to mice and for 25 months to rats. A maximum tolerated dose was not achieved in male mice. There were statistically significant increases in pituitary gland adenomas, endocrine pancreas adenomas, and mammary gland adenocarcinomas. The no-effect dose for these tumors was less than or equal to the MRHD of risperidone based on mg/m
2body surface area (see risperidone package insert). An increase in mammary, pituitary, and endocrine pancreas neoplasms has been found in rodents after chronic administration of other antipsychotic drugs and is considered to be mediated by prolonged dopamine D
2antagonism and hyperprolactinemia. The relevance of these tumor findings in rodents to human risk is unclear
[see
Warnings and Precautions (5.7)]
.
Mutagenesis
No evidence of genotoxic potential for paliperidone was found in the Ames reverse mutation test, the mouse lymphoma assay, or the
in vivo rat micronucleus test.
Impairment of Fertility
In a study of fertility, the percentage of treated female rats that became pregnant was not affected at oral doses of paliperidone of up to 2.5 mg/kg/day which is 2 times the MRHD based on mg/m
2body surface area. However, pre- and post-implantation loss was increased, and the number of live embryos was slightly decreased, at 2.5 mg/kg, a dose that also caused slight maternal toxicity. These parameters were not affected at a dose of 0.63 mg/kg, which is half of the MRHD based on mg/m
2body surface area.
The fertility of male rats was not affected at oral doses of paliperidone of up to 2 times the MRHD of 12 mg/day based on mg/m
2body surface area, although sperm count and sperm viability studies were not conducted with paliperidone. In a subchronic study in Beagle dogs with risperidone, which is extensively converted to paliperidone in dogs and humans, all doses tested (0.31 mg/kg – 5.0 mg/kg) resulted in decreases in serum testosterone and in sperm motility and concentration (0.6 to 10 times the MRHD of 16 mg/day for risperidone, based on mg/m
2body surface area). Serum testosterone and sperm parameters partially recovered, but remained decreased after the last observation (two months after treatment was discontinued).
Adults
The acute efficacy of INVEGA (3 mg to 15 mg once daily) was established in three placebo-controlled and active-controlled (olanzapine), 6-week, fixed-dose trials in non-elderly adult subjects (mean age of 37) who met DSM-IV criteria for schizophrenia. Studies were carried out in North America, Eastern Europe, Western Europe, and Asia. The doses studied among these three trials included 3 mg/day, 6 mg/day, 9 mg/day, 12 mg/day, and 15 mg/day. Dosing was in the morning without regard to meals.
Efficacy was evaluated using the Positive and Negative Syndrome Scale (PANSS), a validated multi-item inventory composed of five factors to evaluate positive symptoms, negative symptoms, disorganized thoughts, uncontrolled hostility/excitement, and anxiety/depression. Efficacy was also evaluated using the Personal and Social Performance (PSP) scale. The PSP is a validated clinician-rated scale that measures personal and social functioning in the domains of socially useful activities (e.g., work and study), personal and social relationships, self-care, and disturbing and aggressive behaviors.
In all 3 studies (n=1665), INVEGA was superior to placebo on the PANSS at all doses. Mean effects at all doses were fairly similar, although the higher doses in all studies were numerically superior. INVEGA was also superior to placebo on the PSP in these trials.
An examination of population subgroups did not reveal any evidence of differential responsiveness on the basis of gender, age (there were few patients over 65), or geographic region. There were insufficient data to explore differential effects based on race.
In a longer-term trial, adult outpatients meeting DSM-IV criteria for schizophrenia who had clinically responded (defined as PANSS score ≤ 70 or ≤ 4 on pre-defined PANSS subscales, as well as having been on a stable fixed dose of INVEGA for the last two weeks of an 8-week run-in phase) were entered into a 6-week open-label stabilization phase where they received INVEGA (doses ranging from 3 mg to 15 mg once daily). After the stabilization phase, patients were randomized in a double-blind manner to either continue on INVEGA at their achieved stable dose, or to placebo, until they experienced a relapse of schizophrenia symptoms. Relapse was pre-defined as significant increase in PANSS (or pre-defined PANSS subscales), hospitalization, clinically significant suicidal or homicidal ideation, or deliberate injury to self or others. An interim analysis of the data showed a significantly longer time to relapse in patients treated with INVEGA compared to placebo, and the trial was stopped early because maintenance of efficacy was demonstrated.
Adolescents
The efficacy of INVEGA in adolescent subjects with schizophrenia was established in a randomized, double-blind, parallel-group, placebo-controlled, 6-week study using a fixed-dose weight-based treatment group design over the dose range of 1.5 to 12 mg/day. The study was carried out in the US, India, Romania, Russia, and Ukraine, and involved subjects 12–17 years of age meeting DSM-IV criteria for schizophrenia, with diagnosis confirmation using the Kiddie Schedule for Affective Disorders and Schizophrenia-Present and Lifetime Version (K-SADS-PL).
Eligible subjects were randomly assigned to 1 of 4 treatment groups: a placebo group or INVEGA Low, Medium, or High dose groups. Doses were administered based on body weight to minimize the risk of exposing lower-weight adolescents to high doses of INVEGA. Subjects weighing between 29 kg and less than 51 kg at the baseline visit were randomly assigned to receive placebo or 1.5 mg (Low dose), 3 mg (Medium dose), or 6 mg (High dose) of INVEGA daily, and subjects weighing at least 51 kg at the baseline visit were randomly assigned to receive placebo or 1.5 mg (Low dose), 6 mg (Medium dose), or 12 mg (High dose) of INVEGA daily. Dosing was in the morning without regard to meals.
Efficacy was evaluated using PANSS. Overall, this study demonstrated the efficacy of INVEGA in adolescents with schizophrenia in the dose range of 3 to 12 mg/day. Doses within this broad range were shown to be effective, however, there was no clear enhancement to efficacy at the higher doses, i.e., 6 mg for subjects weighing less than 51 kg and 12 mg for subjects weighing 51 kg or greater. Although paliperidone was adequately tolerated within the dose range of 3 to 12 mg/day, adverse events were dose related.
Adults
The acute efficacy of INVEGA (3 mg to 12 mg once daily) in the treatment of schizoaffective disorder was established in two placebo-controlled, 6-week trials in non-elderly adult subjects. Enrolled subjects 1) met DSM-IV criteria for schizoaffective disorder, as confirmed by the Structured Clinical Interview for DSM-IV Disorders, 2) had a Positive and Negative Syndrome Scale (PANSS) total score of at least 60, and 3) had prominent mood symptoms as confirmed by a score of at least 16 on the Young Mania Rating Scale and/or Hamilton Rating Scale for Depression. The population included subjects with schizoaffective bipolar and depressive types. In one of these trials, efficacy was assessed in 211 subjects who received flexible doses of INVEGA (3–12 mg once daily). In the other study, efficacy was assessed in 203 subjects who were assigned to one of two dose levels of INVEGA: 6 mg with the option to reduce to 3 mg (n=105) or 12 mg with the option to reduce to 9 mg (n=98) once daily. Both studies included subjects who received INVEGA either as monotherapy [no mood stabilizers and/or antidepressants (55%)] or as an adjunct to mood stabilizers and/or antidepressants (45%). The most commonly used mood stabilizers were valproate and lithium. The most commonly used antidepressants were SSRIs and SNRIs. INVEGA was dosed in the morning without regard to meals. Studies were carried out in the United States, Eastern Europe, Russia, and Asia.
Efficacy was evaluated using the PANSS, a validated multi-item inventory composed of five factors to evaluate positive symptoms, negative symptoms, disorganized thoughts, uncontrolled hostility/excitement, and anxiety/depression. As secondary outcomes, mood symptoms were evaluated using the Hamilton Depression Rating Scale (HAM-D-21) and the Young Mania Rating Scale (YMRS).
The INVEGA group in the flexible-dose study (dosed between 3 and 12 mg/day, mean modal dose of 8.6 mg/day) and the higher dose group of INVEGA in the 2 dose-level study (12 mg/day with option to reduce to 9 mg/day) were each superior to placebo in the PANSS. Numerical improvements in mood symptoms were also observed, as measured by the HAM-D-21 and YMRS. In the lower dose group of the 2 dose-level study (6 mg/day with option to reduce to 3 mg/day), INVEGA was not significantly different from placebo as measured by the PANSS.
Taking the results of both studies together, INVEGA improved the symptoms of schizoaffective disorder at endpoint relative to placebo when administered either as monotherapy or as an adjunct to mood stabilizers and/or antidepressants. An examination of population subgroups did not reveal any evidence of differential responsiveness on the basis of gender, age, or geographic region. There were insufficient data to explore differential effects based on race.
Neuroleptic Malignant Syndrome (NMS)
Counsel patients about a potentially fatal adverse reaction, Neuroleptic Malignant Syndrome (NMS), that has been reported in association with administration of antipsychotic drugs. Advise patients, family members, or caregivers to contact their healthcare provider or report to the emergency room if they experience signs and symptoms of NMS, including hyperpyrexia, muscle rigidity, altered mental status including delirium, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia)
[see
Warnings and Precautions (5.3)].
Tardive Dyskinesia
Counsel patients on the signs and symptoms of tardive dyskinesia and to contact their healthcare provider if these abnormal movements occur
[see
Warnings and Precautions (5.5)].
Metabolic Changes
Educate patients about the risk of metabolic changes, how to recognize symptoms of hyperglycemia and diabetes mellitus, and the need for specific monitoring, including blood glucose, lipids, and weight
[see
Warnings and Precautions (5.6)].
Orthostatic Hypotension
Educate patients about the risk of orthostatic hypotension and syncope, particularly at the time of initiating treatment, re-initiating treatment, or increasing the dose
[see
Warnings and Precautions (5.9)]
.
Leukopenia/Neutropenia
Advise patients with a pre-existing low WBC or a history of drug-induced leukopenia/neutropenia they should have their CBC monitored while taking INVEGA
[see
Warnings and Precautions (5.11)]
.
Hyperprolactinemia
Counsel patients on signs and symptoms of hyperprolactinemia that may be associated with chronic use of INVEGA. Advise them to seek medical attention if they experience any of the following: amenorrhea or galactorrhea in females, erectile dysfunction or gynecomastia in males
[see
Warnings and Precautions (5.7)]
.
Interference with Cognitive and Motor Performance
Caution patients about performing activities requiring mental alertness, such as operating hazardous machinery, or operating a motor vehicle, until they are reasonably certain that INVEGA therapy does not affect them adversely
[see
Warnings and Precautions (5.12)]
.
Priapism
Advise patients of the possibility of painful or prolonged penile erections (priapism). Instruct the patient to seek immediate medical attention in the event of priapism
[see
Warnings and Precautions (5.15)]
.
Heat Exposure and Dehydration
Counsel patients on the importance of avoiding overheating and dehydration
[see
Warnings and Precautions (5.16)]
.
Concomitant Medication
Advise patients to inform their healthcare providers if they are taking, or plan to take, any prescription or over-the-counter drugs, as there is a potential for interactions
[see
Drug Interactions (7)]
.
Alcohol
Advise patients to avoid alcohol while taking INVEGA
[see
Drug Interactions (7.1)]
.
Administration
Patients should be informed that INVEGA should be swallowed whole with the aid of liquids. Tablets should not be chewed, divided, or crushed. The medication is contained within a nonabsorbable shell designed to release the drug at a controlled rate. The tablet shell, along with insoluble core components, is eliminated from the body; patients should not be concerned if they occasionally notice something that looks like a tablet in their stool
[see
Dosage and Administration (2.3)]
.
Pregnancy
Advise patients to notify their healthcare provider if they become pregnant or intend to become pregnant during treatment with INVEGA. Advise patients that INVEGA may cause extrapyramidal and/or withdrawal symptoms in a neonate. Advise patients that there is a pregnancy registry that monitors pregnancy outcomes in women exposed to INVEGA during pregnancy
[see
Use in Specific Populations (8.1)]
.
Lactation
Advise breastfeeding women using INVEGA to monitor infants for somnolence, failure to thrive, jitteriness, and extrapyramidal symptoms (tremors and abnormal muscle movements) and to seek medical care if they notice these signs
[see
Use in Specific Populations (8.2)]
.
Infertility
Advise females of reproductive potential that INVEGA may impair fertility due to an increase in serum prolactin levels. The effects on fertility are reversible
[see
Use in Specific Populations (8.3)].
INVEGA (paliperidone) Extended-Release Tablets
Manufactured for:
Janssen Pharmaceuticals, Inc.
Titusville, NJ 08560, USA
OROS is a registered trademark of ALZA Corporation
For patent information: www.janssenpatents.com
© Johnson & Johnson and its affiliates 2007